Serum NT‑proBNP and TUG1 as novel biomarkers for elderly hypertensive patients with heart failure with preserved ejection fraction

Abstract

Patients with heart failure with preserved ejection fraction (HFPEF) account for ~50% of all cases of heart failure and their clinical prognosis is poor. The present study attempted to investigate the diagnostic value of circulating long non-coding RNA taurine upregulated gene 1 (TUG1) for HFPEF in subjects with hypertension. Between January 2017 and January 2019, 80 aged/elderly hypertensive patients with or without HFPEF were recruited for the present study. The concentration of N-terminal pro-brain natriuretic peptide (NT-proBNP) in the serum was measured using ELISA and TUG1 expression levels were determined using reverse transcription-quantitative PCR. Echocardiography was used for the determination of cardiac function. The results indicated that the levels of NT-proBNP and TUG1 were increased in the serum of hypertensive patients with HFPEF. Pearson analysis demonstrated that NT-proBNP and TUG1 were positively correlated with the left atrial diameter and negatively correlated with the ratio of the peak flow velocity in the early diastolic phase to the peak flow velocity in the late diastolic phase. In addition, a positive correlation was confirmed between TUG1 and NT-proBNP levels. Receiver operating characteristic curve analysis demonstrated that TUG1 and NT-proBNP were useful biomarkers for the diagnosis of HFPEF. In conclusion, it was observed that NT-proBNP and TUG1 were increased in the serum of hypertensive patients with HFPEF. Furthermore, TUG1 and NT-proBNP were indicated to be useful plasma biomarkers for the diagnosis of HFPEF.

Exploration of Potential Genetic Biomarkers for Heart Failure: A Systematic Review

“…The included studies were published between 2007 and 2021. Twenty-three studies were conducted in China [ 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 ]; ten in the United States [ 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 ]; five in Iran [ 47 , 48 , 49 , 50 , 51 ]; four in Italy [ 52 , 53 , 54 , 55 ]; three in the Netherlands [ 56 , 57 , 58 ]; three in Germany [ 59 , 60 , 61 ]; two in Taiwan [ 62 , 63 ]; two in Australia [ 64 , 65 ]; and one each in New Zealand [ 66 …”

“…Nine of the included studies reported the regulation of lncRNA in HF patients [ 23 , 29 , 31 , 34 , 36 , 41 , 53 , 54 , 59 ]. Four studies involved the examination of lncRNA in cardiac tissue, one study in EAT and one in PBMCs.…”

“…Four studies involved the examination of lncRNA in cardiac tissue, one study in EAT and one in PBMCs. In six studies, the modulation of lncRNA in HF patients was validated in peripheral blood [ 23 , 29 , 31 , 34 , 53 , 59 ]. In a study conducted by Greco et al [ 53 ], 13 lncRNAs were significantly modulated (10 up- and 3 downregulated) in HF patients when compared to control subjects.…”

“…Zhang et al demonstrated that the expression of lncRNA taurine upregulated gene 1 ( TUG1 ) is a potentially useful plasma biomarker for the diagnosis of heart failure with preserved ejection fraction (HFpEF). TUG1 was also confirmed to have a positive correlation with major serum marker N-terminal pro-brain natriuretic peptide (NT-proBNP) for HF [ 34 ].…”

Predictive Effect of Triglyceride-Glucose Index on Adverse Prognostic Events in Patients with Type 2 Diabetes Mellitus and Ischemic Cardiomyopathy

“… 4 , 5 HF refers to clinical syndromes characterized by pulmonary and/or body circulation stasis. Because of its high morbidity and mortality, 6 , 7 HF has become a significant contributor to mortality worldwide and a pressing health concern. 8 As a result, early prevention and diagnosis of HF are critical for mitigating relevant symptoms and improving the prognosis of these patients.…”